KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multi-center, single arm study in subjects with advanced
thymic carcinoma after failure of platinum-based combination chemotherapy. Subjects should
have documented progressive disease while on platinum-based combination chemotherapy. If
subjects discontinued platinum-based therapy due to reasons other than progressive disease,
subjects should have completed at least 2 cycles of platinum-based combination chemotherapy
before the commencement of documented progressive disease. Subjects will be treated with
KN046 5 milligram per kilogram every 2 weeks.